drugset / Trial / NCT03185182

Diagnostic Imaging for Clear Cell Renal Cell Carcinoma

NCT03185182 ↗

Phase 2 Terminated 5 enrolled Region Skane Lund University · collab
NaSingle-groupOpen-labelDiagnostic

Summary

The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype.

Timeline

Start
2017-07-14
Primary completion
2018-09-12
Completion
2018-09-12

Outcome

Outcome not reported

Stopped: “Due to "early stopping rule" as defined in the study protocol”

Drugs

EvaluationDrugModalityDoseRoute
Subject ioflupane 123I Unknown 185 mbq Intravenous